Overview

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
Phase:
Phase 2
Details
Lead Sponsor:
Jules Bordet Institute
Collaborators:
KU Leuven
University of Milan
Treatments:
Ketorolac
Pregabalin